President’s Budget will Devastate U.S. Research Enterprise

President’s Budget will Devastate U.S. Research Enterprise

Daniel F. Hayes, MD, FASCO, FACP

Mar 16, 2017

We soundly oppose President Trump’s budget outline, which would cut $6 billion from the National Institutes of Health (NIH). Reducing NIH’s funding by nearly 20% will devastate our nation’s already fragile federal research infrastructure and undercut a longstanding commitment to biomedical science that has fueled advances in cancer prevention, diagnosis, and treatment.

When we are on the cusp of tremendous advances in cancer care, the United States can’t turn back the clock on research that will benefit millions of Americans with life-threatening diseases and their families. Gutting the U.S. research infrastructure won’t make America First, but will decidedly place the United States behind other countries in scientific advances. Failure to nurture the historic U.S. investment in research places health outcomes, scientific leadership, and economic growth at risk.

ASCO urges Congress to reject the proposed cuts and increase federal support for NIH and the National Cancer Institute (NCI).  

We stand ready to work with lawmakers to finalize a fiscal year 2017 (FY 2017) spending package including the $34.1 billion in funding for the NIH passed by the Senate Appropriations Committee in June of last year. We further urge Congress to continue this budget trajectory with significant increases for NIH in FY 2018, in addition to funds included in the 21st Century Cures Act for the Beau Biden Cancer Moonshot Initiative.

Now is not the time to slow progress in finding new treatments and cures for patients with cancer. In fact, after more than a decade of flat funding, our nation’s biomedical research infrastructure must catch up with sustained increases in future years to meet the possibility of today’s science.


The ideas and opinions expressed on the ASCO Connection Blogs do not necessarily reflect those of ASCO. None of the information posted on is intended as medical, legal, or business advice, or advice about reimbursement for health care services. The mention of any product, service, company, therapy or physician practice on does not constitute an endorsement of any kind by ASCO. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in, posted on, or linked to this site, or any errors or omissions.


Daniel E. Castellano, MD

Mar, 20 2017 5:46 AM

Probably the next ASCO could be an excellent opportunity to sign a joint "manifesto" of all countries supporting the cancer research and calling for the withdrawal of the US goverment proposal to cut fundings for NIH/NCI. It´s the opprotunity to set up a ASCO-corner to collect sign of the member and no-member investigators.

Daniel Castellano. Medical Oncologist. Spain 

Daniel F. Hayes, MD, FASCO, FACP

Mar, 20 2017 3:29 PM

Dr. Castellano – thank you for this thoughtful idea. We will monitor this situation and consider how best to productively engage in the coming weeks and months. We appreciate your suggestion in the meantime, and look forward to seeing you in Chicago!


Back to Top